Meeting
2023 ASCO Annual Meeting
Associations between sarcopenia and clinical outcomes in men with metastatic castrate-resistant prostate cancer.
Authors
Efthymios Papadopoulos
University Health Network, Toronto, ON, Canada
Efthymios Papadopoulos , Andy Kin On Wong , Sharon Hiu Ching Law , Lindsey Ze Jing Zhang , Henriette Breunis , Urban Emmenegger , Shabbir M.H. Alibhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Geriatric Models of Care
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12056)
DOI
10.1200/JCO.2023.41.16_suppl.12056
Abstract #
12056
Poster Bd #
424
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Jodi Lyn Layton
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri
Poster
2024 ASCO Genitourinary Cancers Symposium
Time to next systemic therapy after stereotactic body radiation therapy for oligoprogressive metastatic castrate-resistant prostate cancer.
First Author: Corbin J. Eule
Poster
2024 ASCO Genitourinary Cancers Symposium
Days spent with healthcare contact by patients with metastatic castrate-resistant prostate cancer in the last year of life.
First Author: Daniel Sentana Lledo